메뉴 건너뛰기




Volumn 49, Issue 1, 2010, Pages 1-16

Augmented renal clearance: Implications for antibacterial dosing in the critically Ill

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; BIAPENEM; CARBAPENEM DERIVATIVE; CEFEPIME; CEFPIROME; CEFTAZIDIME; CEFTOBIPROLE; CEFTRIAXONE; CILASTATIN; CIPROFLOXACIN; DAPTOMYCIN; DORIPENEM; ERTAPENEM; GATIFLOXACIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PANIPENEM; PIPERACILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; VANCOMYCIN; VASOACTIVE AGENT;

EID: 72249093367     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11318140-000000000-00000     Document Type: Review
Times cited : (324)

References (183)
  • 1
    • 4143078161 scopus 로고    scopus 로고
    • Renal effects of norepinephrine in septic and nonseptic patients
    • Aug
    • Albanese J, Leone M, Garnier F, et al. Renal effects of norepinephrine in septic and nonseptic patients. Chest 2004 Aug; 126 (2): 534-539
    • (2004) Chest , vol.126 , Issue.2 , pp. 534-539
    • Albanese, J.1    Leone, M.2    Garnier, F.3
  • 2
    • 0032929615 scopus 로고    scopus 로고
    • Renal effects of low-dose do-pamine during vasopressor therapy for posttraumatic intracranial hypertension
    • Apr
    • Benmalek F, Behforouz N, Benoist JF, et al. Renal effects of low-dose do-pamine during vasopressor therapy for posttraumatic intracranial hypertension. Intensive Care Med 1999 Apr; 25 (4): 399-405
    • (1999) Intensive Care Med , vol.25 , Issue.4 , pp. 399-405
    • Benmalek, F.1    Behforouz, N.2    Benoist, J.F.3
  • 3
    • 0018977952 scopus 로고
    • Renal function in critically ill post-operative patients: Sequential assessment of creatinine osmolar and free water clearance
    • Feb
    • Brown R, Babcock R, Talbert J, et al. Renal function in critically ill post-operative patients: sequential assessment of creatinine osmolar and free water clearance. Crit Care Med 1980 Feb; 8 (2): 68-72
    • (1980) Crit Care Med , vol.8 , Issue.2 , pp. 68-72
    • Brown, R.1    Babcock, R.2    Talbert, J.3
  • 4
    • 33947202251 scopus 로고    scopus 로고
    • Intermittent administration of cef-tazidime to burns patients: Influence of glomerular filtration
    • Mar
    • Conil JM, Georges B, Fourcade O, et al. Intermittent administration of cef-tazidime to burns patients: influence of glomerular filtration. Int J Clin Pharmacol Ther 2007 Mar; 45 (3): 133-142
    • (2007) Int J Clin Pharmacol Ther , vol.45 , Issue.3 , pp. 133-142
    • Conil, J.M.1    Georges, B.2    Fourcade, O.3
  • 5
    • 33751508210 scopus 로고    scopus 로고
    • Influence of renal function on trough serum concentrations of piperacillin in intensive care unit patients
    • Dec
    • Conil JM, Georges B, Mimoz O, et al. Influence of renal function on trough serum concentrations of piperacillin in intensive care unit patients. Intensive Care Med 2006 Dec; 32 (12): 2063-2066
    • (2006) Intensive Care Med , vol.32 , Issue.12 , pp. 2063-2066
    • Conil, J.M.1    Georges, B.2    Mimoz, O.3
  • 6
    • 51849130398 scopus 로고    scopus 로고
    • Glomerular hyperfiltration and albuminuria in critically ill patients
    • Sep
    • Fuster-Lluch O, Geronimo-Pardo M, Peyro-Garcia R, et al. Glomerular hyperfiltration and albuminuria in critically ill patients. Anaesth Intensive Care 2008 Sep; 36 (5): 674-680
    • (2008) Anaesth Intensive Care , vol.36 , Issue.5 , pp. 674-680
    • Fuster-Lluch, O.1    Geronimo-Pardo, M.2    Peyro-Garcia, R.3
  • 7
    • 0141458039 scopus 로고    scopus 로고
    • Cefepime versus cefpirome:the importance of creatinine clearance
    • Oct
    • LipmanJ, Wallis SC, Boots RJ. Cefepime versus cefpirome:the importance of creatinine clearance. Anesth Analg 2003 Oct; 97 (4): 1149-1154
    • (2003) Anesth Analg , vol.97 , Issue.4 , pp. 1149-1154
    • Lipmanj Wallis, S.C.1    Boots, R.J.2
  • 8
    • 0018141092 scopus 로고
    • Increased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of to-bramycin
    • Oct 26
    • Loirat P, Rohan J, Baillet A, et al. Increased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of to-bramycin. N Engl J Med 1978 Oct 26; 299 (17): 915-919
    • (1978) N Engl J Med , vol.299 , Issue.17 , pp. 915-919
    • Loirat, P.1    Rohan, J.2    Baillet, A.3
  • 9
    • 0023525794 scopus 로고
    • Two-hour versus 22-hour creatinine clear-ance in critically ill patients
    • Dec
    • Sladen RN, Endo E, Harrison T. Two-hour versus 22-hour creatinine clear-ance in critically ill patients. Anesthesiology 1987 Dec; 67 (6): 1013-1016
    • (1987) Anesthesiology , vol.67 , Issue.6 , pp. 1013-1016
    • Sladen, R.N.1    Endo, E.2    Harrison, T.3
  • 10
    • 21844435749 scopus 로고    scopus 로고
    • Should a renal dose of nor-epinephrine stimulate hyperfiltration in head trauma patients?
    • Jun
    • Vincent F, El-Khoury N, Bonnard G, et al. Should a renal dose of nor-epinephrine stimulate hyperfiltration in head trauma patients? Chest 2005 Jun; 127 (6): 2282-2283
    • (2005) Chest , vol.127 , Issue.6 , pp. 2282-2283
    • Vincent, F.1    El-Khoury, N.2    Bonnard, G.3
  • 11
    • 59849085517 scopus 로고    scopus 로고
    • You only find what you look for: The importance of high creatinine clearance in the critically ill
    • Jan
    • Udy A, Roberts JA, Boots RJ, et al. You only find what you look for: the importance of high creatinine clearance in the critically ill. Anaesth Intensive Care 2009 Jan; 37 (1): 11-13
    • (2009) Anaesth Intensive Care , vol.37 , Issue.1 , pp. 11-13
    • Udy, A.1    Roberts, J.A.2    Boots, R.J.3
  • 12
    • 49949099257 scopus 로고    scopus 로고
    • Antibiotic resistance: What's dosing got to do with it?
    • Aug
    • Roberts JA, Kruger P,Paterson DL,et al. Antibiotic resistance: what's dosing got to do with it? Crit Care Med 2008 Aug; 36 (8): 2433-2440
    • (2008) Crit Care Med , vol.36 , Issue.8 , pp. 2433-2440
    • Roberts, J.A.1    Kruger, P.2    Paterson, D.L.3
  • 13
    • 0141610906 scopus 로고    scopus 로고
    • The influence of inadequate anti-microbial treatment of bloodstream infections on patient outcomes in the ICU setting
    • Jul
    • Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate anti-microbial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000 Jul; 118 (1): 146-155
    • (2000) Chest , vol.118 , Issue.1 , pp. 146-155
    • Ibrahim, E.H.1    Sherman, G.2    Ward, S.3
  • 14
    • 0032911760 scopus 로고    scopus 로고
    • Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients
    • Feb
    • Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999 Feb; 115 (2): 462-474
    • (1999) Chest , vol.115 , Issue.2 , pp. 462-474
    • Kollef, M.H.1    Sherman, G.2    Ward, S.3
  • 15
    • 33744527833 scopus 로고    scopus 로고
    • Duration of hypotension before in-itiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock
    • Jun
    • Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before in-itiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006 Jun; 34 (6): 1589-1596
    • (2006) Crit Care Med , vol.34 , Issue.6 , pp. 1589-1596
    • Kumar, A.1    Roberts, D.2    Wood, K.E.3
  • 16
    • 1642456548 scopus 로고    scopus 로고
    • Adequacy of early empiric antibiotic treatment and survival in severe sepsis: Experience from the MONARCS Trial
    • Jan 15
    • MacArthur RD, Miller M, Albertson T, et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS Trial. Clin Infect Dis 2004 Jan 15; 38 (2): 284-288
    • (2004) Clin Infect Dis , vol.38 , Issue.2 , pp. 284-288
    • MacArthur, R.D.1    Miller, M.2    Albertson, T.3
  • 17
    • 1942500844 scopus 로고    scopus 로고
    • Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units
    • Apr
    • Finfer S, Bellomo R, Lipman J, et al. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med 2004 Apr; 30 (4): 589-596
    • (2004) Intensive Care Med , vol.30 , Issue.4 , pp. 589-596
    • Finfer, S.1    Bellomo, R.2    Lipman, J.3
  • 18
    • 0022632883 scopus 로고
    • Vancomycin elimination in patients with burn injury
    • Jun
    • Brater DC, Bawdon RE, Anderson SA, et al. Vancomycin elimination in patients with burn injury. Clin Pharmacol Ther 1986 Jun; 39 (6): 631-634
    • (1986) Clin Pharmacol Ther , vol.39 , Issue.6 , pp. 631-634
    • Brater, D.C.1    Bawdon, R.E.2    Anderson, S.A.3
  • 19
    • 34250662538 scopus 로고    scopus 로고
    • A population pharmacokinetic approach to ceftazidime use in burn patients: Influence of glomerular filtration, gender and mechanical ventilation
    • Jul
    • Conil JM, Georges B, Lavit M, et al. A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilation. Br J Clin Pharmacol 2007 Jul; 64 (1): 27-35
    • (2007) Br J Clin Pharmacol , vol.64 , Issue.1 , pp. 27-35
    • Conil, J.M.1    Georges, B.2
  • 20
    • 34948820309 scopus 로고    scopus 로고
    • Pharmacokinetics of ceftazidime and cefepime in burn patients: The importanceofage and creatinine clearance
    • Oct
    • Conil JM, Georges B, Lavit M, et al. Pharmacokinetics of ceftazidime and cefepime in burn patients: the importanceofage and creatinine clearance. Int J Clin Pharmacol Ther 2007 Oct; 45 (10): 529-538
    • (2007) Int J Clin Pharmacol Ther , vol.45 , Issue.10 , pp. 529-538
    • Conil, J.M.1    Georges, B.2    Lavit, M.3
  • 22
  • 23
    • 0023780462 scopus 로고
    • Altered vancomycin dose vs serum concentration relationship in burn patients
    • Jul
    • Garrelts JC, Peterie JD. Altered vancomycin dose vs serum concentration relationship in burn patients. Clin Pharmacol Ther 1988 Jul; 44 (1): 9-13
    • (1988) Clin Pharmacol Ther , vol.44 , Issue.1 , pp. 9-13
    • Garrelts, J.C.1    Peterie, J.D.2
  • 24
    • 0025366293 scopus 로고
    • Vancomycin pharmacokinetics in burn patients and intravenous drug abusers
    • May
    • Rybak MJ, Albrecht LM, Berman JR, etal. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob Agents Chemother 1990 May; 34 (5): 792-795
    • (1990) Antimicrob Agents Chemother , vol.34 , Issue.5 , pp. 792-795
    • Rybak, M.J.1    Albrecht, L.M.2    Berman, J.R.3
  • 25
    • 59749099847 scopus 로고    scopus 로고
    • Reassessment of recommended imipe-nem doses in febrile neutropenic patients with hematological malignancies
    • Feb
    • Lamoth F, Buclin T, Csajka C, et al. Reassessment of recommended imipe-nem doses in febrile neutropenic patients with hematological malignancies. Antimicrob Agents Chemother 2009 Feb; 53 (2): 785-787
    • (2009) Antimicrob Agents Chemother , vol.53 , Issue.2 , pp. 785-787
    • Lamoth, F.1    Buclin, T.2    Csajka, C.3
  • 26
    • 2342547780 scopus 로고    scopus 로고
    • Teicoplanin in patients with acute leukaemia and febrile neutropenia: A special population benefiting from higher dosages
    • Pea F, Viale P, Candoni A, et al. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages. Clin Pharmacokinet 2004; 43 (6): 405-415
    • (2004) Clin Pharmacokinet , vol.43 , Issue.6 , pp. 405-415
    • Pea, F.1    Viale, P.2    Candoni, A.3
  • 27
    • 0027212644 scopus 로고
    • Vancomycin phar-macokinetics and dosage requirements in hematologic malignancies
    • Jul
    • Fernandez de Gatta MM, Fruns I, Hernandez JM, et al. Vancomycin phar-macokinetics and dosage requirements in hematologic malignancies. Clin Pharm 1993 Jul; 12 (7): 515-520
    • (1993) Clin Pharm , vol.12 , Issue.7 , pp. 515-520
    • Fernandez De Gatta, M.M.1    Fruns, I.2    Hernandez, J.M.3
  • 29
    • 33746784161 scopus 로고    scopus 로고
    • Antibacterial dosing in intensive care: Pharmacoki-netics, degree of disease and pharmacodynamics of sepsis
    • Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacoki-netics, degree of disease and pharmacodynamics of sepsis. Clin Pharmaco-kinet 2006; 45 (8): 755-773
    • (2006) Clin Pharmaco-kinet , vol.45 , Issue.8 , pp. 755-773
    • Roberts, J.A.1    Lipman, J.2
  • 30
    • 33744958852 scopus 로고    scopus 로고
    • Assessing kidney function: Measured and estimated glomerular filtration rate
    • Jun 8
    • Stevens LA, Coresh J, Greene T, et al. Assessing kidney function: measured and estimated glomerular filtration rate. N Engl J Med 2006 Jun 8; 354 (23): 2473-2483
    • (2006) N Engl J Med , vol.354 , Issue.23 , pp. 2473-2483
    • Stevens, L.A.1    Coresh, J.2    Greene, T.3
  • 31
    • 0742288221 scopus 로고    scopus 로고
    • A critical appraisal for definition of hy-perfiltration [letter]
    • Feb author reply 397
    • Sunder-Plassmann G, Horl WH. A critical appraisal for definition of hy-perfiltration [letter]. Am J Kidney Dis 2004 Feb; 43 (2): 396; author reply 397
    • (2004) Am J Kidney Dis , vol.43 , Issue.2 , pp. 396
    • Sunder-Plassmann, G.1    Horl, W.H.2
  • 32
    • 0034012806 scopus 로고    scopus 로고
    • Pharmacokinetic-pharma-codynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis
    • Aug
    • Angus BJ, Smith MD, Suputtamongkol Y, et al. Pharmacokinetic-pharma- codynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. Br J Clin Pharmacol 2000 Aug; 50 (2): 184-191
    • (2000) Br J Clin Pharmacol , vol.50 , Issue.2 , pp. 184-191
    • Angus, B.J.1    Smith, M.D.2    Suputtamongkol, Y.3
  • 33
    • 0141453460 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmaco-dynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors
    • Sep
    • Barbot A, Venisse N, Rayeh F, et al. Pharmacokinetics and pharmaco-dynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors. Intensive Care Med 2003 Sep; 29 (9): 1528-1534
    • (2003) Intensive Care Med , vol.29 , Issue.9 , pp. 1528-1534
    • Barbot, A.1    Venisse, N.2    Rayeh, F.3
  • 34
    • 33947501712 scopus 로고    scopus 로고
    • Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: Pharmacokinetics with special consideration of free-drug concentration
    • Feb
    • Burkhardt O, Kumar V, Katterwe D, et al. Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother 2007 Feb; 59 (2): 277-284
    • (2007) J Antimicrob Chemother , vol.59 , Issue.2 , pp. 277-284
    • Burkhardt, O.1    Kumar, V.2    Katterwe, D.3
  • 35
  • 36
    • 50649101107 scopus 로고    scopus 로고
    • Pharmacokinetic-pharmacodynamic target attainment analysis of biapenem in adult patients: A dosing strategy
    • Ikawa K, Morikawa N, Ikeda K, et al. Pharmacokinetic-pharmacodynamic target attainment analysis of biapenem in adult patients: a dosing strategy. Chemotherapy 2008; 54 (5): 386-394
    • (2008) Chemotherapy , vol.54 , Issue.5 , pp. 386-394
    • Ikawa, K.1    Morikawa, N.2    Ikeda, K.3
  • 37
    • 60249084774 scopus 로고    scopus 로고
    • Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients
    • Mar
    • Ikawa K, Morikawa N, Uehara S, et al. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients. Int J Anti-microb Agents 2009 Mar; 33 (3): 276-279
    • (2009) Int J Anti-microb Agents , vol.33 , Issue.3 , pp. 276-279
    • Ikawa, K.1    Morikawa, N.2    Uehara, S.3
  • 38
    • 23844553605 scopus 로고    scopus 로고
    • Population pharmacokinetics and phar-macodynamics of piperacillin/ tazobactam in patients with complicated intra-abdominal infection
    • Aug
    • Li C, Kuti JL, Nightingale CH, et al. Population pharmacokinetics and phar-macodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother 2005 Aug; 56 (2): 388-395
    • (2005) J Antimicrob Chemother , vol.56 , Issue.2 , pp. 388-395
    • Li, C.1    Kuti, J.L.2    Nightingale, C.H.3
  • 39
    • 0032841482 scopus 로고    scopus 로고
    • Low plasma cefepime levels in critically ill septic patients: Pharmacokinetic modeling indicates improved troughs with revised dosing
    • Oct
    • Lipman J, Wallis SC, Rickard C. Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother 1999 Oct; 43 (10): 2559-2561
    • (1999) Antimicrob Agents Chemother , vol.43 , Issue.10 , pp. 2559-2561
    • Lipman, J.1    Wallis, S.C.2    Rickard, C.3
  • 40
    • 0035096092 scopus 로고    scopus 로고
    • Low cefpirome levels during twice daily dosing in critically ill septic patients: Pharmacokinetic modelling calls for more frequent dosing
    • Feb
    • Lipman J, Wallis SC, Rickard CM, et al. Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. Intensive Care Med 2001 Feb; 27 (2): 363-370
    • (2001) Intensive Care Med , vol.27 , Issue.2 , pp. 363-370
    • Lipman, J.1    Wallis, S.C.2    Rickard, C.M.3
  • 41
    • 0030802009 scopus 로고    scopus 로고
    • Intermittent bolus dosing of ceftazidime in critically ill patients
    • Aug
    • Young RJ, Lipman J, Gin T, et al. Intermittent bolus dosing of ceftazidime in critically ill patients. J Antimicrob Chemother 1997 Aug; 40 (2): 269-273
    • (1997) J Antimicrob Chemother , vol.40 , Issue.2 , pp. 269-273
    • Young, R.J.1    Lipman, J.2    Gin, T.3
  • 42
    • 0026710191 scopus 로고
    • Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. the ACCP/SCCM Consensus Conference Committee American College of Chest Physicians/ Society of Critical Care Medicine
    • Jun
    • Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee, American College of Chest Physicians/ Society of Critical Care Medicine. Chest 1992 Jun; 101 (6): 1644-1655
    • (1992) Chest , vol.101 , Issue.6 , pp. 1644-1655
    • Bone, R.C.1    Balk, R.A.2    Cerra, F.B.3
  • 43
    • 33746077716 scopus 로고    scopus 로고
    • The inflammatory response to surgery and trau-ma
    • Aug
    • Kohl BA, Deutschman CS. The inflammatory response to surgery and trau-ma. Curr Opin Crit Care 2006 Aug; 12 (4): 325-332
    • (2006) Curr Opin Crit Care , vol.12 , Issue.4 , pp. 325-332
    • Kohl, B.A.1    Deutschman, C.S.2
  • 44
    • 33645563636 scopus 로고    scopus 로고
    • Postoperative metabolic and cir-culatory responses in patients that express SIRS after major digestive surgery
    • Mar-Apr
    • Ishikawa M, Nishioka M, Hanaki N, et al. Postoperative metabolic and cir-culatory responses in patients that express SIRS after major digestive surgery. Hepatogastroenterology 2006 Mar-Apr; 53 (68): 228-233
    • (2006) Hepatogastroenterology , vol.53 , Issue.68 , pp. 228-233
    • Ishikawa, M.1    Nishioka, M.2    Hanaki, N.3
  • 45
    • 0037396875 scopus 로고    scopus 로고
    • 2001 SCCM/ESICM/ACCP/ATS/ SIS International Sepsis Definitions Conference
    • Apr
    • Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/ SIS International Sepsis Definitions Conference. Intensive Care Med 2003 Apr; 29 (4): 530-538
    • (2003) Intensive Care Med , vol.29 , Issue.4 , pp. 530-538
    • Levy, M.M.1    Fink, M.P.2    Marshall, J.C.3
  • 46
    • 0025303027 scopus 로고
    • Septic shock in humans: Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy
    • Aug 1
    • Parrillo JE, Parker MM, Natanson C, et al. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990 Aug 1; 113 (3): 227-242
    • (1990) Ann Intern Med , vol.113 , Issue.3 , pp. 227-242
    • Parrillo, J.E.1    Parker, M.M.2    Natanson, C.3
  • 47
    • 0141465216 scopus 로고    scopus 로고
    • Vital organ blood flow during hyperdynamic sepsis
    • Sep
    • Di Giantomasso D, May CN, Bellomo R. Vital organ blood flow during hyperdynamic sepsis. Chest 2003 Sep; 124 (3): 1053-1059
    • (2003) Chest , vol.124 , Issue.3 , pp. 1053-1059
    • Di Giantomasso, D.1    May, C.N.2    Bellomo, R.3
  • 48
    • 37549020378 scopus 로고    scopus 로고
    • Surviving Sepsis Campaign: Inter-national guidelines for management of severe sepsis and septic shock: 2008
    • Jan
    • Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: inter-national guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008 Jan; 36 (1): 296-327
    • (2008) Crit Care Med , vol.36 , Issue.1 , pp. 296-327
    • Dellinger, R.P.1    Levy, M.M.2    Carlet, J.M.3
  • 49
    • 0035829842 scopus 로고    scopus 로고
    • Early goal-directed therapy in the treatment of severe sepsis and septic shock
    • Nov 8
    • Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001 Nov 8; 345 (19): 1368-1377
    • (2001) N Engl J Med , vol.345 , Issue.19 , pp. 1368-1377
    • Rivers, E.1    Nguyen, B.2    Havstad, S.3
  • 50
    • 34250816257 scopus 로고    scopus 로고
    • The effects of normal and hypertonic saline on regional blood flow and oxygen delivery
    • Jul
    • Wan L, Bellomo R, May CN. The effects of normal and hypertonic saline on regional blood flow and oxygen delivery. Anesth Analg 2007 Jul; 105 (1): 141-147
    • (2007) Anesth Analg , vol.105 , Issue.1 , pp. 141-147
    • Wan, L.1    Bellomo, R.2    May, C.N.3
  • 51
    • 41649100721 scopus 로고    scopus 로고
    • Vasoactive drugs and acute kidney injury
    • Apr
    • Bellomo R, Wan L, May C. Vasoactive drugs and acute kidney injury. Crit Care Med 2008 Apr; 36 (4 Suppl.): S179-86
    • (2008) Crit Care Med , vol.36 , Issue.4 SUPPL.
    • Bellomo, R.1    Wan, L.2    May, C.3
  • 52
  • 53
    • 0242539679 scopus 로고    scopus 로고
    • Norepinephrine and vital organ blood flow during experimental hyperdynamic sepsis
    • DOI 10.1007/s00134-003-1736-9
    • Di Giantomasso D, May CN, Bellomo R. Norepinephrine and vital organ blood flow during experimental hyperdynamic sepsis. Intensive Care Med 2003 Oct; 29 (10): 1774-1781 (Pubitemid 37373824)
    • (2003) Intensive Care Medicine , vol.29 , Issue.10 , pp. 1774-1781
    • Di Giantomasso, D.1    May, C.N.2    Bellomo, R.3
  • 54
    • 0032946252 scopus 로고    scopus 로고
    • Effectsof norepinephrine on the renal vasculature in normal and endotoxemic dogs
    • Apr
    • Bellomo R, Kellum JA, Wisniewski SR, et al. Effectsof norepinephrine on the renal vasculature in normal and endotoxemic dogs. Am J Respir Crit Care Med 1999 Apr; 159 (4 Pt 1): 1186-1192
    • (1999) Am J Respir Crit Care Med , vol.159 , Issue.4 PART 1 , pp. 1186-1192
    • Bellomo, R.1    Kellum, J.A.2    Wisniewski, S.R.3
  • 55
    • 0024410955 scopus 로고
    • Norepinephrine therapy has no dele-terious renal effects in human septic shock
    • May
    • Desjars P, Pinaud M, Bugnon D, et al. Norepinephrine therapy has no dele-terious renal effects in human septic shock. Crit Care Med 1989 May; 17 (5): 426-429
    • (1989) Crit Care Med , vol.17 , Issue.5 , pp. 426-429
    • Desjars, P.1    Pinaud, M.2    Bugnon, D.3
  • 56
    • 0025239776 scopus 로고
    • Renal effects of norepinephrine used to treat septic shock patients
    • Mar
    • Marin C, Eon B, Saux P, et al. Renal effects of norepinephrine used to treat septic shock patients. Crit Care Med 1990 Mar; 18 (3): 282-285
    • (1990) Crit Care Med , vol.18 , Issue.3 , pp. 282-285
    • Marin, C.1    Eon, B.2    Saux, P.3
  • 57
    • 0027204645 scopus 로고
    • The effects of nor-epinephrine on hemodynamics and renal function in severe septic shock states
    • Redl-Wenzl EM, Armbruster C, Edelmann G, et al. The effects of nor-epinephrine on hemodynamics and renal function in severe septic shock states. Intensive Care Med 1993; 19 (3): 151-154
    • (1993) Intensive Care Med , vol.19 , Issue.3 , pp. 151-154
    • Redl-Wenzl, E.M.1    Armbruster, C.2    Edelmann, G.3
  • 58
    • 41649102467 scopus 로고    scopus 로고
    • Pathophysiology of septic acute kidney injury: What do we really know?
    • Apr
    • Wan L, Bagshaw SM, Langenberg C, et al. Pathophysiology of septic acute kidney injury: what do we really know? Crit Care Med 2008 Apr; 36 (4 Suppl.): S198-203
    • (2008) Crit Care Med , vol.36 , Issue.4 SUPPL.
    • Wan, L.1    Bagshaw, S.M.2    Langenberg, C.3
  • 59
    • 34548229961 scopus 로고    scopus 로고
    • Septic acute kidney injury in cri-tically ill patients: Clinical characteristics and outcomes
    • May
    • Bagshaw SM, Uchino S, Bellomo R, et al. Septic acute kidney injury in cri-tically ill patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol 2007 May; 2 (3): 431-439
    • (2007) Clin J Am Soc Nephrol , vol.2 , Issue.3 , pp. 431-439
    • Bagshaw, S.M.1    Uchino, S.2    Bellomo, R.3
  • 60
    • 17144425396 scopus 로고    scopus 로고
    • Assessment of renal function in recently admitted critically ill patients with normal serum creatinine
    • Apr
    • Hoste EA, Damen J, Vanholder RC, et al. Assessment of renal function in recently admitted critically ill patients with normal serum creatinine. Nephrol Dial Transplant 2005 Apr; 20 (4): 747-753
    • (2005) Nephrol Dial Transplant , vol.20 , Issue.4 , pp. 747-753
    • Hoste, E.A.1    Damen, J.2    Vanholder, R.C.3
  • 61
    • 0031741197 scopus 로고    scopus 로고
    • Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey
    • Dec
    • Jones CA, McQuillan GM, Kusek JW, et al. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 1998 Dec; 32 (6): 992-999
    • (1998) Am J Kidney Dis , vol.32 , Issue.6 , pp. 992-999
    • Jones, C.A.1    McQuillan, G.M.2    Kusek, J.W.3
  • 62
    • 34748906005 scopus 로고    scopus 로고
    • Low baseline serum creatinine con-centration predicts mortality in critically ill patients independent of body mass index
    • Oct
    • Cartin-Ceba R, Afessa B, Gajic O. Low baseline serum creatinine con-centration predicts mortality in critically ill patients independent of body mass index. Crit Care Med 2007 Oct; 35 (10): 2420-2423
    • (2007) Crit Care Med , vol.35 , Issue.10 , pp. 2420-2423
    • Cartin-Ceba, R.1    Afessa, B.2    Gajic, O.3
  • 63
    • 0033574249 scopus 로고    scopus 로고
    • A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group
    • Mar 16
    • Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999 Mar 16; 130 (6): 461-470
    • (1999) Ann Intern Med , Issue.130 , pp. 461-470
    • Levey, A.S.1    Bosch, J.P.2    Lewis, J.B.3
  • 64
    • 0141455302 scopus 로고    scopus 로고
    • A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease
    • Oct
    • Lin J, Knight EL, Hogan ML, et al. A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J Am Soc Nephrol 2003 Oct; 14 (10): 2573-2580
    • (2003) J Am Soc Nephrol , vol.14 , Issue.10 , pp. 2573-2580
    • Lin, J.1    Knight, E.L.2    Hogan, M.L.3
  • 65
    • 20544476937 scopus 로고    scopus 로고
    • Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease
    • DOI 10.1681/ASN.2004060447
    • Poggio ED, Wang X, Greene T, et al. Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 2005 Feb; 16 (2): 459-466 (Pubitemid 41725142)
    • (2005) Journal of the American Society of Nephrology , vol.16 , Issue.2 , pp. 459-466
    • Poggio, E.D.1    Wang, X.2    Greene, T.3    Van Lente, F.4    Hall, P.M.5
  • 66
    • 19944368397 scopus 로고    scopus 로고
    • Using serum creatinine to estimate glomerular filtration rate: Accuracy in good health and in chronic kidney disease
    • Dec 21
    • Rule AD, Larson TS, Bergstralh EJ, et al. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 2004 Dec 21; 141 (12): 929-937
    • (2004) Ann Intern Med , vol.141 , Issue.12 , pp. 929-937
    • Rule, A.D.1    Larson, T.S.2    Bergstralh, E.J.3
  • 67
    • 0016916438 scopus 로고
    • Prediction of creatinine clearance from serum creatinine
    • Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16 (1): 31-41
    • (1976) Nephron , vol.16 , Issue.1 , pp. 31-41
    • Cockcroft, D.W.1    Gault, M.H.2
  • 68
    • 34247327462 scopus 로고    scopus 로고
    • Assessment of renal function in clinical practice at the bedside of burn patients
    • May
    • Conil JM, Georges B, Fourcade O, et al. Assessment of renal function in clinical practice at the bedside of burn patients. Br J Clin Pharmacol 2007 May; 63 (5): 583-594
    • (2007) Br J Clin Pharmacol , vol.63 , Issue.5 , pp. 583-594
    • Conil, J.M.1    Georges, B.2    Fourcade, O.3
  • 69
    • 0028808871 scopus 로고
    • Accuracy of estimated creatinine clearance in obese patients with stable renal function in the intensive care unit
    • Nov-Dec
    • Snider RD, Kruse JA, Bander JJ, et al. Accuracy of estimated creatinine clearance in obese patients with stable renal function in the intensive care unit. Pharmacotherapy 1995 Nov-Dec; 15 (6): 747-753
    • (1995) Pharmacotherapy , vol.15 , Issue.6 , pp. 747-753
    • Snider, R.D.1    Kruse, J.A.2    Bander, J.J.3
  • 70
    • 22844436304 scopus 로고    scopus 로고
    • Performance of the cockcroft-gault and modification of diet in renal disease equations in estimating GFR in Ill hospitalized patients
    • DOI 10.1053/j.ajkd.2005.04.023, PII S027263860500569X
    • Poggio ED, Nef PC, Wang X, et al. Performance of the Cockcroft-Gault and modification of diet in renal disease equations in estimating GFR in ill hospitalized patients. Am J Kidney Dis 2005 Aug; 46 (2): 242-252 (Pubitemid 41040352)
    • (2005) American Journal of Kidney Diseases , vol.46 , Issue.2 , pp. 242-252
    • Poggio, E.D.1    Nef, P.C.2    Wang, X.3    Greene, T.4    Van Lente, F.5    Dennis, V.W.6    Hall, P.M.7
  • 71
    • 0036044490 scopus 로고    scopus 로고
    • Estimation of creatinine clearance in patients with unstable renal function, withoutaurine specimen
    • Jul-Aug
    • Jelliffe R. Estimation of creatinine clearance in patients with unstable renal function, withoutaurine specimen. Am J Nephrol 2002 Jul-Aug;22(4): 320-324
    • (2002) Am J Nephrol , vol.22 , Issue.4 , pp. 320-324
    • Jelliffe, R.1
  • 72
    • 35448984655 scopus 로고    scopus 로고
    • Replacement of 24-h creatinine clearance by 2-h creatinine clearance in intensive care unit patients: A single-center study
    • Nov
    • Herrera-Gutierrez ME, Seller-Perez G, Banderas-Bravo E,et al. Replacement of 24-h creatinine clearance by 2-h creatinine clearance in intensive care unit patients: a single-center study. Intensive Care Med 2007 Nov; 33 (11): 1900-1906
    • (2007) Intensive Care Med , vol.33 , Issue.11 , pp. 1900-1906
    • Herrera-Gutierrez, M.E.1    Seller-Perez, G.2    Banderas-Bravo, E.3
  • 73
    • 22044439231 scopus 로고    scopus 로고
    • AbdolellM,etal. 12-hour versus 24-hour creatinineclearance in critically ill pediatric patients
    • Jul
    • PongS,SetoW, AbdolellM,etal. 12-hour versus 24-hour creatinineclearance in critically ill pediatric patients. Pediatr Res 2005 Jul; 58 (1): 83-88
    • (2005) Pediatr Res , vol.58 , Issue.1 , pp. 83-88
    • Pong, S.1    Seto, W.2
  • 74
    • 0030966795 scopus 로고    scopus 로고
    • Measurements of glomerular filtration in the intensive care unit are only a rough guide to renal function
    • Feb
    • Wells M, Lipman J. Measurements of glomerular filtration in the intensive care unit are only a rough guide to renal function. S Afr J Surg 1997 Feb; 35 (1): 20-23
    • (1997) S Afr J Surg , vol.35 , Issue.1 , pp. 20-23
    • Wells, M.1    Lipman, J.2
  • 75
    • 0030946674 scopus 로고    scopus 로고
    • Pitfalls in the prediction of renal function in the intensive care unit: A review
    • Feb
    • Wells M, Lipman J. Pitfalls in the prediction of renal function in the intensive care unit: a review. S Afr J Surg 1997 Feb; 35 (1): 16-19
    • (1997) S Afr J Surg , vol.35 , Issue.1 , pp. 16-19
    • Wells, M.1    Lipman, J.2
  • 76
    • 0031947633 scopus 로고    scopus 로고
    • Drug interactions at the renal level: Implications for drug development
    • May
    • Bonate PL, Reith K, Weir S. Drug interactions at the renal level: implications for drug development. Clin Pharmacokinet 1998 May; 34 (5): 375-404
    • (1998) Clin Pharmacokinet , vol.34 , Issue.5 , pp. 375-404
    • Bonate, P.L.1    Reith, K.2    Weir, S.3
  • 77
    • 0018472223 scopus 로고
    • Use of serum creatinine concentrations to determine renal function
    • May-Jun
    • Bjornsson TD. Use of serum creatinine concentrations to determine renal function. Clin Pharmacokinet 1979 May-Jun; 4 (3): 200-222
    • (1979) Clin Pharmacokinet , vol.4 , Issue.3 , pp. 200-222
    • Bjornsson, T.D.1
  • 78
    • 0031753158 scopus 로고    scopus 로고
    • Determination of inulin clearance by bolus intravenous injection in healthy subjects and ascitic patients: Equivalence of systemic and renal clearances as glomerular filtration markers
    • Dec
    • Orlando R, Floreani M, Padrini R, et al. Determination of inulin clearance by bolus intravenous injection in healthy subjects and ascitic patients: equivalence of systemic and renal clearances as glomerular filtration markers. Br J Clin Pharmacol 1998 Dec; 46 (6): 605-609
    • (1998) Br J Clin Pharmacol , vol.46 , Issue.6 , pp. 605-609
    • Orlando, R.1    Floreani, M.2    Padrini, R.3
  • 79
    • 1842289168 scopus 로고    scopus 로고
    • Sinistrin clearance for de-terminationofglomerular filtration rate:areappraisalofvarious approaches using a new analytical method
    • Aug
    • Buclin T, Pechere-Bertschi A, Sechaud R, et al. Sinistrin clearance for de-terminationofglomerular filtration rate:areappraisalofvarious approaches using a new analytical method. J Clin Pharmacol 1997 Aug; 37 (8): 679-692
    • (1997) J Clin Pharmacol , vol.37 , Issue.8 , pp. 679-692
    • Buclin, T.1    Pechere-Bertschi, A.2    Sechaud, R.3
  • 80
    • 41649095757 scopus 로고    scopus 로고
    • New biomarkers of acute kidney injury
    • Parikh CR, Devarajan P. New biomarkers of acute kidney injury. Crit Care Med 2008 Apr; 36 (4 Suppl.): S159-65
    • (2008) Crit Care Med , vol.36
    • Parikh, C.R.1    Devarajan, P.2
  • 81
    • 0034825501 scopus 로고    scopus 로고
    • Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: Absenceofa pharmacokinetic interaction between fluconazole and sinistrin, p-amino-hippuric acid and pindolol
    • Jun
    • Gross AS, McLachlan AJ, Minns I, et al. Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absenceofa pharmacokinetic interaction between fluconazole and sinistrin, p-amino-hippuric acid and pindolol. Br J Clin Pharmacol 2001 Jun; 51 (6): 547-555
    • (2001) Br J Clin Pharmacol , vol.51 , Issue.6 , pp. 547-555
    • Gross, A.S.1    McLachlan, A.J.2    Minns, I.3
  • 82
    • 0035132763 scopus 로고    scopus 로고
    • Analytical validation for a series of marker compounds used to assess renal drug elimination processes
    • Feb
    • McLachlan AJ, Gross AS, Beal JL, et al. Analytical validation for a series of marker compounds used to assess renal drug elimination processes. Ther Drug Monit 2001 Feb; 23 (1): 39-46
    • (2001) Ther Drug Monit , vol.23 , Issue.1 , pp. 39-46
    • McLachlan, A.J.1    Gross, A.S.2    Beal, J.L.3
  • 83
    • 0025037894 scopus 로고
    • Effects of treatment and the metabolic response to injury on drug clearance: A prospective study with piperacillin
    • Jan
    • Shikuma LR, Ackerman BH, Weaver RH, et al. Effects of treatment and the metabolic response to injury on drug clearance: a prospective study with piperacillin. Crit Care Med 1990 Jan; 18 (1): 37-41
    • (1990) Crit Care Med , vol.18 , Issue.1 , pp. 37-41
    • Shikuma, L.R.1    Ackerman, B.H.2    Weaver, R.H.3
  • 84
    • 0033006752 scopus 로고    scopus 로고
    • Pharmacokinetics of cefpirome during the posttraumatic systemic inflammatory response syndrome
    • May
    • Jacolot A, Incagnoli P, Edouard AR, et al. Pharmacokinetics of cefpirome during the posttraumatic systemic inflammatory response syndrome. Intensive Care Med 1999 May; 25 (5): 486-491
    • (1999) Intensive Care Med , vol.25 , Issue.5 , pp. 486-491
    • Jacolot, A.1    Incagnoli, P.2    Edouard, A.R.3
  • 85
    • 43549110221 scopus 로고    scopus 로고
    • Influence of glomerular filtration rate on the clearance of vancomycin administered by continuous infusion in burn patients
    • Jun
    • Dailly E, Le Floch R, Deslandes G, et al. Influence of glomerular filtration rate on the clearance of vancomycin administered by continuous infusion in burn patients. Int J Antimicrob Agents 2008 Jun; 31 (6): 537-539
    • (2008) Int J Antimicrob Agents , vol.31 , Issue.6 , pp. 537-539
    • Dailly, E.1    Le Floch, R.2    Deslandes, G.3
  • 86
    • 0030977390 scopus 로고    scopus 로고
    • Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis
    • Lugo G, Castaneda-Hernandez G. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Crit Care Med 1997 May; 25 (5): 806-811
    • (1997) Crit Care Med , vol.25 , Issue.5 , pp. 806-811
    • Lugo, G.1    Castaneda-Hernandez, G.2
  • 87
    • 0031952586 scopus 로고    scopus 로고
    • Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
    • quiz 11-12
    • Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998 Jan; 26 (1): 1-10; quiz 11-12
    • (1998) Clin Infect Dis , vol.26 , Issue.1 , pp. 1-10
    • Craig, W.A.1
  • 88
    • 0023119430 scopus 로고
    • Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration
    • Jan
    • Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987 Jan; 155 (1): 93-99
    • (1987) J Infect Dis , vol.155 , Issue.1 , pp. 93-99
    • Moore, R.D.1    Lietman, P.S.2    Smith, C.R.3
  • 89
    • 0027161344 scopus 로고
    • Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
    • May
    • Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993 May; 37 (5): 1073-1081
    • (1993) Antimicrob Agents Chemother , vol.37 , Issue.5 , pp. 1073-1081
    • Forrest, A.1    Nix, D.E.2    Ballow, C.H.3
  • 90
    • 29244442296 scopus 로고    scopus 로고
    • The pharmacokinetic and pharmacodynamic properties of van-comycin
    • Jan
    • Rybak MJ. The pharmacokinetic and pharmacodynamic properties of van-comycin. Clin Infect Dis 2006 Jan 1; 42 Suppl. 1: S35-9
    • (2006) Clin Infect Dis , vol.1 , Issue.42 SUPPL. 1
    • Rybak, M.J.1
  • 91
    • 0031856680 scopus 로고    scopus 로고
    • The pharmacodynamics of beta-lactams
    • Jul
    • Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998 Jul; 27 (1): 10-22
    • (1998) Clin Infect Dis , vol.27 , Issue.1 , pp. 10-22
    • Turnidge, J.D.1
  • 92
    • 0022491927 scopus 로고
    • Kinetics of antimicrobial activity
    • May
    • Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr 1986 May; 108 (5 Pt 2): 835-840
    • (1986) J Pediatr , vol.108 , Issue.5 PART 2 , pp. 835-840
    • Vogelman, B.1    Craig, W.A.2
  • 94
    • 0026551574 scopus 로고
    • Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects
    • Mar
    • Barbhaiya RH, Forgue ST, Gleason CR, et al. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob Agents Chemother 1992 Mar; 36 (3): 552-557
    • (1992) Antimicrob Agents Chemother , vol.36 , Issue.3 , pp. 552-557
    • Barbhaiya, R.H.1    Forgue, S.T.2    Gleason, C.R.3
  • 95
    • 41849100736 scopus 로고    scopus 로고
    • Cefepime in intensive care unit patients: Validation of a population pharmacokinetic approach and influence of covariables
    • Apr
    • Georges B, Conil JM, Seguin T, et al. Cefepime in intensive care unit patients: validation of a population pharmacokinetic approach and influence of covariables. Int J Clin Pharmacol Ther 2008 Apr; 46 (4): 157-164
    • (2008) Int J Clin Pharmacol Ther , vol.46 , Issue.4 , pp. 157-164
    • Georges, B.1    Conil, J.M.2    Seguin, T.3
  • 96
    • 0027764336 scopus 로고
    • Pharmacokinetics of cefepime in patients with the sepsis syndrome
    • Nov
    • Kieft H, Hoepelman AI, Knupp CA, et al. Pharmacokinetics of cefepime in patients with the sepsis syndrome. J Antimicrob Chemother 1993 Nov; 32 Suppl. B: 117-122
    • (1993) J Antimicrob Chemother , vol.32 , Issue.SUPPL. B , pp. 117-122
    • Kieft, H.1    Hoepelman, A.I.2    Knupp, C.A.3
  • 97
    • 0036313816 scopus 로고    scopus 로고
    • Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis
    • Jul
    • Joukhadar C, Klein N, Mayer BX, et al. Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis. Crit Care Med 2002 Jul; 30 (7): 1478-1482
    • (2002) Crit Care Med , vol.30 , Issue.7 , pp. 1478-1482
    • Joukhadar, C.1    Klein, N.2    Mayer, B.X.3
  • 99
    • 0035051828 scopus 로고    scopus 로고
    • The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients
    • Apr
    • Joynt GM, Lipman J, Gomersall CD, et al. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother 2001 Apr; 47 (4): 421-429
    • (2001) J Antimicrob Chemother , vol.47 , Issue.4 , pp. 421-429
    • Joynt, G.M.1    Lipman, J.2    Gomersall, C.D.3
  • 100
    • 0025200259 scopus 로고
    • Clearance of ceftriaxone in critical care patients with acute renal failure
    • Heinemeyer G, Link J, Weber W, et al. Clearance of ceftriaxone in critical care patients with acute renal failure. Intensive Care Med 1990; 16 (7): 448-453
    • (1990) Intensive Care Med , vol.16 , Issue.7 , pp. 448-453
    • Heinemeyer, G.1    Link, J.2    Weber, W.3
  • 101
    • 0023100364 scopus 로고
    • Influence of protein binding and severity of illness on renal elimination of four cephalosporin drugs in intensive-care patients
    • Apr
    • Van Dalen R, Vree T, Baars IM. Influence of protein binding and severity of illness on renal elimination of four cephalosporin drugs in intensive-care patients. Pharm Weekbl Sci 1987 Apr; 9 (2): 98-103
    • (1987) Pharm Weekbl Sci , vol.9 , Issue.2 , pp. 98-103
    • Van Dalen, R.1    Vree, T.2    Baars, I.M.3
  • 102
    • 0020568308 scopus 로고
    • Pharmacokinetics of ceftazidime in male and female volunteers
    • Jun
    • Sommers DK, Walters L, Van Wyk M, et al. Pharmacokinetics of ceftazidime in male and female volunteers. Antimicrob Agents Chemother 1983 Jun; 23 (6): 892-896
    • (1983) Antimicrob Agents Chemother , vol.23 , Issue.6 , pp. 892-896
    • Sommers, D.K.1    Walters, L.2    Van Wyk, M.3
  • 103
    • 0033799928 scopus 로고    scopus 로고
    • Intermittent and continuous cefta-zidime infusion for critically ill trauma patients
    • Jun
    • Hanes SD, Wood GC, Herring V, et al. Intermittent and continuous cefta-zidime infusion for critically ill trauma patients. Am J Surg 2000 Jun; 179 (6): 436-440
    • (2000) Am J Surg , vol.179 , Issue.6 , pp. 436-440
    • Hanes, S.D.1    Wood, G.C.2    Herring, V.3
  • 104
    • 0344483897 scopus 로고    scopus 로고
    • Altered pharmacokinetics of cefta-zidime in critically ill patients
    • Jul
    • Gomez CM, Cordingly JJ, Palazzo MG. Altered pharmacokinetics of cefta-zidime in critically ill patients. Antimicrob Agents Chemother 1999 Jul; 43 (7): 1798-1802
    • (1999) Antimicrob Agents Chemother , vol.43 , Issue.7 , pp. 1798-1802
    • Gomez, C.M.1    Cordingly, J.J.2    Palazzo, M.G.3
  • 105
    • 0036158038 scopus 로고    scopus 로고
    • Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections
    • Jan
    • Buijk SL, Gyssens IC, Mouton JW, et al. Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections. J Anti-microb Chemother 2002 Jan; 49 (1): 121-128
    • (2002) J Anti-microb Chemother , vol.49 , Issue.1 , pp. 121-128
    • Buijk, S.L.1    Gyssens, I.C.2    Mouton, J.W.3
  • 107
    • 62849124143 scopus 로고    scopus 로고
    • Piperacillin penetration into tissue of critically ill patients with sepsis: Bolus versus continuous administration?
    • Mar
    • Roberts JA, Roberts MS, Robertson TA, et al. Piperacillin penetration into tissue of critically ill patients with sepsis: bolus versus continuous administration? Crit Care Med 2009 Mar; 37 (3): 926-933
    • (2009) Crit Care Med , vol.37 , Issue.3 , pp. 926-933
    • Roberts, J.A.1    Roberts, M.S.2    Robertson, T.A.3
  • 108
    • 0024466149 scopus 로고
    • The pharmacokinetics of meropenem in volunteers
    • Sep
    • Bax RP, Bastain W, Featherstone A, et al. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother 1989 Sep; 24 Suppl. A: 311-320
    • (1989) J Antimicrob Chemother , vol.24 , Issue.SUPPL. A , pp. 311-320
    • Bax, R.P.1    Bastain, W.2    Featherstone, A.3
  • 109
    • 19544392338 scopus 로고    scopus 로고
    • Pharmacokinetic evaluation of mer-openem and imipenem in critically ill patients with sepsis
    • Novelli A, Adembri C, Livi P, et al. Pharmacokinetic evaluation of mer-openem and imipenem in critically ill patients with sepsis. Clin Pharmaco-kinet 2005; 44 (5): 539-549
    • (2005) Clin Pharmaco-kinet , vol.44 , Issue.5 , pp. 539-549
    • Novelli, A.1    Adembri, C.2    Livi, P.3
  • 110
    • 0036177106 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmaco-dynamics of meropenem in critically ill patients
    • Feb
    • Kitzes-Cohen R, Farin D, Piva G, et al. Pharmacokinetics and pharmaco-dynamics of meropenem in critically ill patients. Int J Antimicrob Agents 2002 Feb; 19 (2): 105-110
    • (2002) Int J Antimicrob Agents , vol.19 , Issue.2 , pp. 105-110
    • Kitzes-Cohen, R.1    Farin, D.2    Piva, G.3
  • 111
    • 39449096286 scopus 로고    scopus 로고
    • Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock
    • Mar
    • Karjagin J, Lefeuvre S, Oselin K, et al. Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock. Clin Pharmacol Ther 2008 Mar; 83 (3): 452-459
    • (2008) Clin Pharmacol Ther , vol.83 , Issue.3 , pp. 452-459
    • Karjagin, J.1    Lefeuvre, S.2    Oselin, K.3
  • 112
    • 0029131506 scopus 로고
    • The pharmacokinetics of mer-openem in surgical patients with moderate or severe infections
    • Jul
    • Lovering AM, Vickery CJ, Watkin DS, et al. The pharmacokinetics of mer-openem in surgical patients with moderate or severe infections. J Antimicrob Chemother 1995 Jul; 36 (1): 165-172
    • (1995) J Antimicrob Chemother , vol.36 , Issue.1 , pp. 165-172
    • Lovering, A.M.1    Vickery, C.J.2    Watkin, D.S.3
  • 113
    • 0345130000 scopus 로고    scopus 로고
    • Continuous infusion versus intermittent administration of meropenem in critically ill patients
    • Apr
    • Thalhammer F, Traunmuller F, El Menyawi I, et al. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 1999 Apr; 43 (4): 523-527
    • (1999) J Antimicrob Chemother , vol.43 , Issue.4 , pp. 523-527
    • Thalhammer, F.1    Traunmuller, F.2    El Menyawi, I.3
  • 114
    • 67449090359 scopus 로고    scopus 로고
    • Meropenem dosing in cri-tically ill patients with sepsis and without renal dysfunction: Intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution
    • Jul
    • Roberts JA, Kirkpatrick CM, Roberts MS, et al. Meropenem dosing in cri-tically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009 Jul; 64 (1): 142-150
    • (2009) J Antimicrob Chemother , vol.64 , Issue.1 , pp. 142-150
    • Roberts, J.A.1    Kirkpatrick, C.M.2    Roberts, M.S.3
  • 115
    • 0021024704 scopus 로고
    • Pharmacokinetics of imipenem in healthy volunteers
    • Dec
    • Norrby SR, Bjornegard B, Ferber F, et al. Pharmacokinetics of imipenem in healthy volunteers. J Antimicrob Chemother 1983 Dec; 12 Suppl. D: 109-124
    • (1983) J Antimicrob Chemother , vol.12 , Issue.SUPPL. D , pp. 109-124
    • Norrby, S.R.1    Bjornegard, B.2    Ferber, F.3
  • 116
    • 0036095347 scopus 로고    scopus 로고
    • Tissue distribution of imipenem in critically ill patients
    • May
    • Tegeder I, Schmidtko A, Brautigam L, et al. Tissue distribution of imipenem in critically ill patients. Clin Pharmacol Ther 2002 May; 71 (5): 325-333
    • (2002) Clin Pharmacol Ther , vol.71 , Issue.5 , pp. 325-333
    • Tegeder, I.1    Schmidtko, A.2    Brautigam, L.3
  • 117
    • 35948970570 scopus 로고    scopus 로고
    • Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipe-nem-cilastatin in critically ill patients in a randomized, controlled trial
    • Sep
    • Sakka SG, Glauner AK, Bulitta JB, et al. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipe-nem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 2007 Sep; 51 (9): 3304-3310
    • (2007) Antimicrob Agents Chemother , vol.51 , Issue.9 , pp. 3304-3310
    • Sakka, S.G.1    Glauner, A.K.2    Bulitta, J.B.3
  • 118
    • 0036841274 scopus 로고    scopus 로고
    • Pharmacokinetics of ertapenem in healthy young volunteers
    • Nov
    • Majumdar AK, Musson DG, Birk KL, et al. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob Agents Chemother 2002 Nov; 46 (11): 3506-3511
    • (2002) Antimicrob Agents Chemother , vol.46 , Issue.11 , pp. 3506-3511
    • Majumdar, A.K.1    Musson, D.G.2    Birk, K.L.3
  • 119
    • 63149089185 scopus 로고    scopus 로고
    • Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis
    • May
    • Brink AJ, Richards GA, Schillack V, et al. Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis. Int J Anti-microb Agents 2009 May; 33 (5): 432-436
    • (2009) Int J Anti-microb Agents , vol.33 , Issue.5 , pp. 432-436
    • Brink, A.J.1    Richards, G.A.2    Schillack, V.3
  • 120
    • 33751505966 scopus 로고    scopus 로고
    • Pharmacokinetics and lung concentra-tions of ertapenem in patients with ventilator-associated pneumonia
    • Dec
    • Boselli E, Breilh D, Saux MC, et al. Pharmacokinetics and lung concentra-tions of ertapenem in patients with ventilator-associated pneumonia. Intensive Care Med 2006 Dec; 32 (12): 2059-2062
    • (2006) Intensive Care Med , vol.32 , Issue.12 , pp. 2059-2062
    • Boselli, E.1    Breilh, D.2    Saux, M.C.3
  • 121
    • 34247616140 scopus 로고    scopus 로고
    • Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria
    • May
    • Roos JF, Lipman J, Kirkpatrick CM. Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria. Intensive Care Med 2007 May; 33 (5): 781-788
    • (2007) Intensive Care Med , vol.33 , Issue.5 , pp. 781-788
    • Roos, J.F.1    Lipman, J.2    Kirkpatrick, C.M.3
  • 122
    • 0037764683 scopus 로고    scopus 로고
    • Pharmacokinetics and pharma-codynamics of cefepime in patients with various degrees of renal function
    • Jun
    • Tam VH, McKinnon PS, Akins RL, et al. Pharmacokinetics and pharma-codynamics of cefepime in patients with various degrees of renal function. Antimicrob Agents Chemother 2003 Jun; 47 (6): 1853-1861
    • (2003) Antimicrob Agents Chemother , vol.47 , Issue.6 , pp. 1853-1861
    • Tam, V.H.1    McKinnon, P.S.2    Akins, R.L.3
  • 124
    • 0033804883 scopus 로고    scopus 로고
    • Comparative pharmaco-kinetics of the carbapenems: Clinical implications
    • Sep
    • Mouton JW, Touzw DJ, Horrevorts AM, et al. Comparative pharmaco-kinetics of the carbapenems: clinical implications. Clin Pharmacokinet 2000 Sep; 39 (3): 185-201
    • (2000) Clin Pharmacokinet , vol.39 , Issue.3 , pp. 185-201
    • Mouton, J.W.1    Touzw, D.J.2    Horrevorts, A.M.3
  • 125
    • 0021738711 scopus 로고
    • Postantibiotic effect of imi-penem on Pseudomonas aeruginosa
    • Nov
    • Bustamante CI, Drusano GL, Tatem BA, et al. Postantibiotic effect of imi-penem on Pseudomonas aeruginosa. Antimicrob Agents Chemother 1984 Nov; 26 (5): 678-682
    • (1984) Antimicrob Agents Chemother , vol.26 , Issue.5 , pp. 678-682
    • Bustamante, C.I.1    Drusano, G.L.2    Tatem, B.A.3
  • 126
    • 0037439449 scopus 로고    scopus 로고
    • Prevention of resistance: A goal for dose selection for anti-microbial agents
    • Jan 15
    • Drusano GL. Prevention of resistance: a goal for dose selection for anti-microbial agents. Clin Infect Dis 2003 Jan 15; 36 Suppl. 1: S42-50
    • (2003) Clin Infect Dis , vol.36 , Issue.SUPPL. 1
    • Drusano, G.L.1
  • 127
    • 33947497591 scopus 로고    scopus 로고
    • Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study
    • Feb
    • Roberts JA, Boots R, Rickard CM, et al. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. J Antimicrob Chemother 2007 Feb; 59 (2): 285-291
    • (2007) J Antimicrob Chemother , vol.59 , Issue.2 , pp. 285-291
    • Roberts, J.A.1    Boots, R.2    Rickard, C.M.3
  • 128
    • 0033059826 scopus 로고    scopus 로고
    • Continuous infusion ceftazidime in intensive care: A randomized controlled trial
    • Feb
    • Lipman J, Gomersall CD, Gin T, et al. Continuous infusion ceftazidime in intensive care: a randomized controlled trial. J Antimicrob Chemother 1999 Feb; 43 (2): 309-311
    • (1999) J Antimicrob Chemother , vol.43 , Issue.2 , pp. 309-311
    • Lipman, J.1    Gomersall, C.D.2    Gin, T.3
  • 129
    • 23144461310 scopus 로고    scopus 로고
    • Cefepime in critically ill patients: Continuous infusion vs an intermittent dosing regimen
    • Aug
    • Georges B, Conil JM, Cougot P, et al. Cefepime in critically ill patients: continuous infusion vs an intermittent dosing regimen. Int J Clin Pharmacol Ther 2005 Aug; 43 (8): 360-369
    • (2005) Int J Clin Pharmacol Ther , vol.43 , Issue.8 , pp. 360-369
    • Georges, B.1    Conil, J.M.2    Cougot, P.3
  • 130
    • 0035011945 scopus 로고    scopus 로고
    • Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia
    • McNabb JJ, Nightingale CH, Quintiliani R, et al. Cost-effectiveness of cef-tazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia. Pharmacotherapy 2001 May; 21 (5): 549-555 (Pubitemid 32411052)
    • (2001) Pharmacotherapy , vol.21 , Issue.5 , pp. 549-555
    • McNabb, J.J.1    Nightingale, C.H.2    Quintiliani, R.3    Nicolau, D.P.4
  • 131
    • 0030985564 scopus 로고    scopus 로고
    • Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion
    • Apr
    • Mouton JW, Vinks AA, Punt NC. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother 1997 Apr; 41 (4): 733-738
    • (1997) Antimicrob Agents Chemother , vol.41 , Issue.4 , pp. 733-738
    • Mouton, J.W.1    Vinks, A.A.2    Punt, N.C.3
  • 132
    • 0035001026 scopus 로고    scopus 로고
    • Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia
    • DOI 10.1016/S0924-8579(01)00329-6, PII S0924857901003296
    • Nicolau DP, McNabb J, Lacy MK, et al. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001 Jun; 17 (6): 497-504 (Pubitemid 32492970)
    • (2001) International Journal of Antimicrobial Agents , vol.17 , Issue.6 , pp. 497-504
    • Nicolau, D.P.1    McNabb, J.2    Lacy, M.K.3    Quintiliani, R.4    Nightingale, C.H.5
  • 133
    • 34249866197 scopus 로고    scopus 로고
    • Continuous infusion of beta-lactam antibiotics in severe infections: A review of its role
    • Jul
    • Roberts JA, Paratz J, Paratz E, et al. Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents 2007 Jul; 30 (1): 11-18
    • (2007) Int J Antimicrob Agents , vol.30 , Issue.1 , pp. 11-18
    • Roberts, J.A.1    Paratz, J.2    Paratz, E.3
  • 134
    • 33846442436 scopus 로고    scopus 로고
    • Piperacillin-tazobactam for Pseu-domonas aeruginosa infection: Clinical implications of an extended-infusion dosing strategy
    • Feb 1
    • Lodise Jr TP, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseu-domonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007 Feb 1; 44 (3): 357-363
    • (2007) Clin Infect Dis , vol.44 , Issue.3 , pp. 357-363
    • Lodise Jr, T.P.1    Lomaestro, B.2    Drusano, G.L.3
  • 135
    • 33144478109 scopus 로고    scopus 로고
    • Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to Gram-negative bacilli
    • Feb
    • Lorente L, Lorenzo L, Martin MM, et al. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to Gram-negative bacilli. Ann Pharmacother 2006 Feb; 40 (2): 219-223
    • (2006) Ann Pharmacother , vol.40 , Issue.2 , pp. 219-223
    • Lorente, L.1    Lorenzo, L.2    Martin, M.M.3
  • 136
    • 63149188101 scopus 로고    scopus 로고
    • Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion
    • May
    • Lorente L, Jimenez A, Martin MM, et al. Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 2009 May; 33 (5): 464-468
    • (2009) Int J Antimicrob Agents , vol.33 , Issue.5 , pp. 464-468
    • Lorente, L.1    Jimenez, A.2    Martin, M.M.3
  • 137
    • 37349091127 scopus 로고    scopus 로고
    • Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: A retrospective, nonrandomized, open-label, historical chart review
    • Nov
    • Lorente L, Jimenez A, Palmero S, et al. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review. Clin Ther 2007 Nov; 29 (11): 2433-2439
    • (2007) Clin Ther , vol.29 , Issue.11 , pp. 2433-2439
    • Lorente, L.1    Jimenez, A.2    Palmero, S.3
  • 138
    • 66449092115 scopus 로고    scopus 로고
    • A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics
    • Jun
    • Roberts JA, Webb SA, Paterson DL, et al. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med 2009 Jun; 37 (6): 2071-2078
    • (2009) Crit Care Med , vol.37 , Issue.6 , pp. 2071-2078
    • Roberts, J.A.1    Webb, S.A.2    Paterson, D.L.3
  • 139
    • 0025308247 scopus 로고
    • Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rateonefficacy of teicoplaninin a rabbit model of endocarditis
    • Apr
    • Chambers HF, Kennedy S. Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rateonefficacy of teicoplaninin a rabbit model of endocarditis. Antimicrob Agents Chemother 1990 Apr; 34 (4): 510-514
    • (1990) Antimicrob Agents Chemother , vol.34 , Issue.4 , pp. 510-514
    • Chambers, H.F.1    Kennedy, S.2
  • 140
    • 0029796793 scopus 로고    scopus 로고
    • The concentration-independent effect of monoexponential and biexponential decay in vancomycin con-centrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions
    • Oct
    • Larsson AJ, Walker KJ, Raddatz JK, et al. The concentration-independent effect of monoexponential and biexponential decay in vancomycin con-centrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. J Antimicrob Chemother 1996 Oct; 38 (4): 589-597
    • (1996) J Antimicrob Chemother , vol.38 , Issue.4 , pp. 589-597
    • Larsson, A.J.1    Walker, K.J.2    Raddatz, J.K.3
  • 141
    • 0344936720 scopus 로고    scopus 로고
    • In vitro studies of pharmacodynamic prop-erties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis
    • Oct
    • Lowdin E, Odenholt I, Cars O. In vitro studies of pharmacodynamic prop-erties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1998 Oct; 42 (10): 2739-2744
    • (1998) Antimicrob Agents Chemother , vol.42 , Issue.10 , pp. 2739-2744
    • Lowdin, E.1    Odenholt, I.2    Cars, O.3
  • 142
    • 0034102326 scopus 로고    scopus 로고
    • Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylo-coccus aureus infection
    • May
    • Knudsen JD, Fuursted K, Raber S, et al. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylo-coccus aureus infection. Antimicrob Agents Chemother 2000 May; 44 (5): 1247-1254
    • (2000) Antimicrob Agents Chemother , vol.44 , Issue.5 , pp. 1247-1254
    • Knudsen, J.D.1    Fuursted, K.2    Raber, S.3
  • 143
    • 0347694556 scopus 로고    scopus 로고
    • Basic pharmacodynamics of antibacterials with clinical applica-tions to the use of beta-lactams, glycopeptides, and linezolid
    • Sep
    • Craig WA. Basic pharmacodynamics of antibacterials with clinical applica-tions to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003 Sep; 17 (3): 479-501
    • (2003) Infect Dis Clin North Am , vol.17 , Issue.3 , pp. 479-501
    • Craig, W.A.1
  • 144
    • 7444254040 scopus 로고    scopus 로고
    • Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections
    • Moise-Broder PA, Forrest A, Birmingham MC, et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43 (13): 925-942
    • (2004) Clin Pharmacokinet , vol.43 , Issue.13 , pp. 925-942
    • Moise-Broder, P.A.1    Forrest, A.2    Birmingham, M.C.3
  • 145
    • 0034090794 scopus 로고    scopus 로고
    • High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures
    • Mar
    • Pea F, Porreca L, Baraldo M, et al. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother 2000 Mar; 45 (3): 329-335
    • (2000) J Antimicrob Chemother , vol.45 , Issue.3 , pp. 329-335
    • Pea, F.1    Porreca, L.2    Baraldo, M.3
  • 146
    • 0027982027 scopus 로고
    • Vancomycin pharmacokinetics in a patient population: Effect of age, gender, and body weight
    • Oct
    • Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit 1994 Oct; 16 (5): 513-518
    • (1994) Ther Drug Monit , vol.16 , Issue.5 , pp. 513-518
    • Ducharme, M.P.1    Slaughter, R.L.2    Edwards, D.J.3
  • 147
    • 33748344038 scopus 로고    scopus 로고
    • Population pharmacokinetic para-meters of vancomycin in critically ill patients
    • Oct
    • Llopis-Salvia P, Jimenez-Torres NV. Population pharmacokinetic para-meters of vancomycin in critically ill patients. J Clin Pharm Ther 2006 Oct; 31 (5): 447-454
    • (2006) J Clin Pharm Ther , vol.31 , Issue.5 , pp. 447-454
    • Llopis-Salvia, P.1    Jimenez-Torres, N.V.2
  • 148
    • 66149108761 scopus 로고    scopus 로고
    • Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in the critically ill patients
    • May
    • Pea F, Furlanut M, Negri C, et al. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in the critically ill patients. Antimicrob Agents Che-mother 2009 May; 53 (5): 1863-1867
    • (2009) Antimicrob Agents Che-mother , vol.53 , Issue.5 , pp. 1863-1867
    • Pea, F.1    Furlanut, M.2    Negri, C.3
  • 149
    • 0025931885 scopus 로고
    • Pharmacokinetics and tolerability of teicoplanin in healthy volunteers after single increasing doses
    • Dec
    • Del Favero A, Patoia L, Rosina R, et al. Pharmacokinetics and tolerability of teicoplanin in healthy volunteers after single increasing doses. Antimicrob Agents Chemother 1991 Dec; 35 (12): 2551-2557
    • (1991) Antimicrob Agents Chemother , vol.35 , Issue.12 , pp. 2551-2557
    • Del Favero, A.1    Patoia, L.2    Rosina, R.3
  • 150
    • 0037395975 scopus 로고    scopus 로고
    • Teicoplanin therapeutic drug monitoring in critically ill patients: A retrospective study emphasizing the importance of a loading dose
    • Apr
    • Pea F, Brollo L, Viale P, et al. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. J Antimicrob Chemother 2003 Apr; 51 (4): 971-975
    • (2003) J Antimicrob Chemother , vol.51 , Issue.4 , pp. 971-975
    • Pea, F.1    Brollo, L.2    Viale, P.3
  • 151
    • 17944367778 scopus 로고    scopus 로고
    • Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: Prospective multicenter randomized study
    • Sep
    • Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001 Sep; 45 (9): 2460-2467
    • (2001) Antimicrob Agents Chemother , vol.45 , Issue.9 , pp. 2460-2467
    • Wysocki, M.1    Delatour, F.2    Faurisson, F.3
  • 152
    • 24944459102 scopus 로고    scopus 로고
    • Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides
    • Sep
    • Rello J, Sole-Violan J, Sa-Borges M, et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 2005 Sep; 33 (9): 1983-1987
    • (2005) Crit Care Med , vol.33 , Issue.9 , pp. 1983-1987
    • Rello, J.1    Sole-Violan, J.2    Sa-Borges, M.3
  • 153
    • 53249113145 scopus 로고    scopus 로고
    • Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis
    • Nov
    • Brink AJ, Richards GA, Cummins RR, et al. Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis. Int J Antimicrob Agents 2008 Nov; 32 (5): 455-458
    • (2008) Int J Antimicrob Agents , vol.32 , Issue.5 , pp. 455-458
    • Brink, A.J.1    Richards, G.A.2    Cummins, R.R.3
  • 154
    • 0033800132 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of teicoplanin
    • Sep
    • Wilson AP. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 2000 Sep; 39 (3): 167-183
    • (2000) Clin Pharmacokinet , vol.39 , Issue.3 , pp. 167-183
    • Wilson, A.P.1
  • 155
    • 33646414510 scopus 로고    scopus 로고
    • Steady-state trough serum and epi-thelial lining fluid concentrations of teicoplanin 12mg/kg per day in patients with ventilator-associated pneumonia
    • May
    • Mimoz O, Rolland D, Adoun M, et al. Steady-state trough serum and epi-thelial lining fluid concentrations of teicoplanin 12mg/kg per day in patients with ventilator-associated pneumonia. Intensive Care Med 2006 May;32 (5): 775-779
    • (2006) Intensive Care Med , vol.32 , Issue.5 , pp. 775-779
    • Mimoz, O.1    Rolland, D.2    Adoun, M.3
  • 156
    • 0027457842 scopus 로고
    • Pharmacodynamics of a fluoro-quinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis
    • Mar
    • Drusano GL, Johnson DE, Rosen M, et al. Pharmacodynamics of a fluoro-quinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993 Mar; 37 (3): 483-490
    • (1993) Antimicrob Agents Chemother , vol.37 , Issue.3 , pp. 483-490
    • Drusano, G.L.1    Johnson, D.E.2    Rosen, M.3
  • 157
    • 0031940776 scopus 로고    scopus 로고
    • Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy
    • Mar
    • Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998 Mar; 42 (3): 521-527
    • (1998) Antimicrob Agents Chemother , vol.42 , Issue.3 , pp. 521-527
    • Thomas, J.K.1    Forrest, A.2    Bhavnani, S.M.3
  • 158
    • 55549148730 scopus 로고    scopus 로고
    • Ciprofloxacin use in critically ill patients: Pharmacokinetic and pharmacodynamic approaches
    • Dec
    • Conil JM, Georges B, de Lussy A, et al. Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches. Int J Anti-microb Agents 2008 Dec; 32 (6): 505-510
    • (2008) Int J Anti-microb Agents , vol.32 , Issue.6 , pp. 505-510
    • Conil, J.M.1    Georges, B.2    De Lussy, A.3
  • 159
    • 49749094394 scopus 로고    scopus 로고
    • Ciprofloxacin pharmacokinetics in critically ill patients: A prospective cohort study
    • Sep
    • van Zanten AR, Polderman KH, van Geijlswijk IM, et al. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care 2008 Sep; 23 (3): 422-430
    • (2008) J Crit Care , vol.23 , Issue.3 , pp. 422-430
    • Van Zanten, A.R.1    Polderman, K.H.2    Van Geijlswijk, I.M.3
  • 160
    • 0037707561 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia
    • Pea F, Di Qual E, Cusenza A, et al. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. Clin Pharmacokinet 2003; 42 (6): 589-598
    • (2003) Clin Pharmacokinet , vol.42 , Issue.6 , pp. 589-598
    • Pea, F.1    Di Qual, E.2    Cusenza, A.3
  • 161
    • 0031663388 scopus 로고    scopus 로고
    • Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis
    • The Baragwanath Ciprofloxacin Study Group Sep
    • Lipman J, Scribante J, Gous AG, et al. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. Antimicrob Agents Chemother 1998 Sep; 42 (9): 2235-2239
    • (1998) Antimicrob Agents Chemother , vol.42 , Issue.9 , pp. 2235-2239
    • Lipman, J.1    Scribante, J.2    Gous, A.G.3
  • 162
    • 26444552033 scopus 로고    scopus 로고
    • Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: A report from the OPTAMA Program
    • Oct
    • Sun HK, Kuti JL, Nicolau DP. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program. Crit Care Med 2005 Oct; 33 (10): 2222-2227
    • (2005) Crit Care Med , vol.33 , Issue.10 , pp. 2222-2227
    • Sun, H.K.1    Kuti, J.L.2    Nicolau, D.P.3
  • 163
    • 4444327303 scopus 로고    scopus 로고
    • Clinical applications of levofloxacin for severe infections
    • Graninger W, Zeitlinger M. Clinical applications of levofloxacin for severe infections. Chemotherapy 2004; 50 Suppl. 1: 16-21
    • (2004) Chemotherapy , vol.50 , Issue.SUPPL. 1 , pp. 16-21
    • Graninger, W.1    Zeitlinger, M.2
  • 164
    • 0001011923 scopus 로고    scopus 로고
    • Antimicrobial agents: The aminoglycosides
    • Goodman LS, Limberd LE, Milinoff PB, et al., editors 9th ed. New York: McGraw Hill
    • Chambers HF, Sande MA. Antimicrobial agents: the aminoglycosides. In: Goodman LS, Limberd LE, Milinoff PB, et al., editors. Goodman and Gilman's: the pharmacological basis of therapeutics. 9th ed. New York: McGraw Hill, 1996: 1103-1121
    • (1996) Goodman and gilman'S: The Pharmacological Basis of Therapeutics , pp. 1103-1121
    • Chambers, H.F.1    Sande, M.A.2
  • 165
    • 3943064336 scopus 로고    scopus 로고
    • Effect of once-daily dosing vs mul-tiple daily dosing of tobramycin on enzyme markers of nephrotoxicity
    • Aug
    • Olsen KM, Rudis MI, Rebuck JA, et al. Effect of once-daily dosing vs mul-tiple daily dosing of tobramycin on enzyme markers of nephrotoxicity. Crit Care Med 2004 Aug; 32 (8): 1678-1682
    • (2004) Crit Care Med , vol.32 , Issue.8 , pp. 1678-1682
    • Olsen, K.M.1    Rudis, M.I.2    Rebuck, J.A.3
  • 166
    • 0027518301 scopus 로고
    • Once versus thrice daily gentamicin in patients with serious infections
    • Feb 6
    • Prins JM, Buller HR, Kuijper EJ, et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993 Feb 6; 341 (8841): 335-339
    • (1993) Lancet , vol.341 , Issue.8841 , pp. 335-339
    • Prins, J.M.1    Buller, H.R.2    Kuijper, E.J.3
  • 167
    • 0032979927 scopus 로고    scopus 로고
    • Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria
    • Mar
    • Kashuba AD, Nafziger AN, Drusano GL, et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria. Antimicrob Agents Chemother 1999 Mar; 43 (3): 623-629
    • (1999) Antimicrob Agents Chemother , vol.43 , Issue.3 , pp. 623-629
    • Kashuba, A.D.1    Nafziger, A.N.2    Drusano, G.L.3
  • 168
    • 0024210968 scopus 로고
    • Altered aminoglycoside pharma-cokinetics in the critically ill
    • Nov
    • Beckhouse MJ, Whyte IM, Byth PL, et al. Altered aminoglycoside pharma-cokinetics in the critically ill. Anaesth Intensive Care 1988 Nov; 16 (4): 418-422
    • (1988) Anaesth Intensive Care , vol.16 , Issue.4 , pp. 418-422
    • Beckhouse, M.J.1    Whyte, I.M.2    Byth, P.L.3
  • 169
    • 0032771862 scopus 로고    scopus 로고
    • Population pharmacoki-netics of amikacin in patients with haematological malignancies
    • Aug
    • Romano S, Fdez de Gatta MM, Calvo MV, et al. Population pharmacoki-netics of amikacin in patients with haematological malignancies. J Anti-microb Chemother 1999 Aug; 44 (2): 235-242
    • (1999) J Anti-microb Chemother , vol.44 , Issue.2 , pp. 235-242
    • Romano, S.1    Fdez De Gatta, M.M.2    Calvo, M.V.3
  • 170
    • 33747114646 scopus 로고    scopus 로고
    • Increased amikacin dosage require-ments in burn patients receiving a once-daily regimen
    • Sep
    • Conil JM, Georges B, Breden A, et al. Increased amikacin dosage require-ments in burn patients receiving a once-daily regimen. Int J Antimicrob Agents 2006 Sep; 28 (3): 226-230
    • (2006) Int J Antimicrob Agents , vol.28 , Issue.3 , pp. 226-230
    • Conil, J.M.1    Georges, B.2    Breden, A.3
  • 171
    • 57749107966 scopus 로고    scopus 로고
    • Suboptimal aminoglycoside dosing in critically ill patients
    • Dec
    • Rea RS, Capitano B, Bies R, et al. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit 2008 Dec; 30 (6): 674-681
    • (2008) Ther Drug Monit , vol.30 , Issue.6 , pp. 674-681
    • Rea, R.S.1    Capitano, B.2    Bies, R.3
  • 172
    • 19644388857 scopus 로고    scopus 로고
    • Daptomycin: A novel cyclic lipopeptide antimicrobial
    • Jun 1
    • Schriever CA, Fernandez C, Rodvold KA, et al. Daptomycin: a novel cyclic lipopeptide antimicrobial. Am J Health Syst Pharm 2005 Jun 1; 62 (11): 1145-1158
    • (2005) Am J Health Syst Pharm , vol.62 , Issue.11 , pp. 1145-1158
    • Schriever, C.A.1    Fernandez, C.2    Rodvold, K.A.3
  • 173
    • 0347992764 scopus 로고    scopus 로고
    • In vivo pharmacodynamic activity of dap-tomycin
    • Jan
    • Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of dap-tomycin. Antimicrob Agents Chemother 2004 Jan; 48 (1): 63-68
    • (2004) Antimicrob Agents Chemother , vol.48 , Issue.1 , pp. 63-68
    • Safdar, N.1    Andes, D.2    Craig, W.A.3
  • 174
    • 59749092290 scopus 로고    scopus 로고
    • Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever
    • Feb
    • Bubalo JS, Munar MY, Cherala G, et al. Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrob Agents Chemother 2009 Feb; 53 (2): 428-434
    • (2009) Antimicrob Agents Chemother , vol.53 , Issue.2 , pp. 428-434
    • Bubalo, J.S.1    Munar, M.Y.2    Cherala, G.3
  • 175
    • 0038778571 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections
    • May
    • MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Anti-microb Chemother 2003 May; 51 Suppl. 2: ii17-25
    • (2003) J Anti-microb Chemother , vol.51 , Issue.SUPPL. 2
    • MacGowan, A.P.1
  • 176
    • 0042925335 scopus 로고    scopus 로고
    • Pharmacokinetics of linezolid in subjects with renal dysfunction
    • Sep
    • Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 2003 Sep; 47 (9): 2775-2780
    • (2003) Antimicrob Agents Chemother , vol.47 , Issue.9 , pp. 2775-2780
    • Brier, M.E.1    Stalker, D.J.2    Aronoff, G.R.3
  • 177
    • 0036839738 scopus 로고    scopus 로고
    • In vivo pharmacodynamics of a new oxazolidinone (linezolid)
    • Nov
    • Andes D, van Ogtrop ML, Peng J, et al. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002 Nov; 46 (11): 3484-3489
    • (2002) Antimicrob Agents Chemother , vol.46 , Issue.11 , pp. 3484-3489
    • Andes, D.1    Van Ogtrop, M.L.2    Peng, J.3
  • 178
    • 0036239725 scopus 로고    scopus 로고
    • Pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia
    • May
    • Gentry-Nielsen MJ, Olsen KM, Preheim LC. Pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia. Antimicrob Agents Chemother 2002 May; 46 (5): 1345-1351
    • (2002) Antimicrob Agents Chemother , vol.46 , Issue.5 , pp. 1345-1351
    • Gentry-Nielsen, M.J.1    Olsen, K.M.2    Preheim, L.C.3
  • 179
    • 37549032134 scopus 로고    scopus 로고
    • Linezolid pharmacokinetic/ pharmacodynamic profile in critically ill septic patients: Intermittent versus continuous infusion
    • Feb
    • Adembri C, Fallani S, Cassetta MI, et al. Linezolid pharmacokinetic/ pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents 2008 Feb; 31 (2): 122-129
    • (2008) Int J Antimicrob Agents , vol.31 , Issue.2 , pp. 122-129
    • Adembri, C.1    Fallani, S.2    Cassetta, M.I.3
  • 180
    • 37549000548 scopus 로고    scopus 로고
    • Effect of severity of sepsis on tissue concentrations of linezolid
    • Jan
    • Thallinger C, Buerger C, Plock N, et al. Effect of severity of sepsis on tissue concentrations of linezolid. J Antimicrob Chemother 2008 Jan; 61 (1): 173-176
    • (2008) J Antimicrob Chemother , vol.61 , Issue.1 , pp. 173-176
    • Thallinger, C.1    Buerger, C.2    Plock, N.3
  • 181
    • 0028925096 scopus 로고
    • Experience with a once-daily aminoglycoside program administered to 2,184 adult patients
    • Mar
    • Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995 Mar; 39 (3): 650-655
    • (1995) Antimicrob Agents Chemother , vol.39 , Issue.3 , pp. 650-655
    • Nicolau, D.P.1    Freeman, C.D.2    Belliveau, P.P.3
  • 182
    • 0031662683 scopus 로고    scopus 로고
    • Pharmacodynamics pharmacokinetics, and therapeutic drug monitoring of glycopeptides
    • Oct
    • MacGowan AP. Pharmacodynamics pharmacokinetics, and therapeutic drug monitoring of glycopeptides. Ther Drug Monit 1998 Oct; 20 (5): 473-477
    • (1998) Ther Drug Monit , vol.20 , Issue.5 , pp. 473-477
    • MacGowan, A.P.1
  • 183
    • 62849095029 scopus 로고    scopus 로고
    • Pharmacokinetic issues for antibiotics in the critically ill patient
    • Mar quiz 859
    • Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009 Mar; 37 (3): 840-51; quiz 859
    • (2009) Crit Care Med , vol.37 , Issue.3 , pp. 840-851
    • Roberts, J.A.1    Lipman, J.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.